n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with betulinic acid in 2 studies
Studies (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Trials (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Recent Studies (post-2010) (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Studies (betulinic acid) | Trials (betulinic acid) | Recent Studies (post-2010) (betulinic acid) |
---|---|---|---|---|---|
79 | 1 | 16 | 1,025 | 1 | 676 |
Protein | Taxonomy | n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50) | betulinic acid (IC50) |
---|---|---|---|
Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | 11.2 | |
SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | 11.2 | |
SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | 11.2 | |
Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 2 | |
DNA polymerase beta | Rattus norvegicus (Norway rat) | 6.5 | |
Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 1.5 | |
5'-nucleotidase | Homo sapiens (human) | 7.28 | |
Non-structural protein 1 | Dengue virus | 1.7 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and betulinic acid
Article | Year |
---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |